Tessa Therapeutics Ltd: Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of Off the Shelf CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH)

Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X) in patients with relapsed or refractory CD30-positive lymphomas Results demonstrate

Related Keywords

United States ,Singapore ,American ,Malcolm Brenner ,Kostenloser Wertpapierhandel ,Ivan Horak ,Johanna Bennett ,Carlos Ramos ,Dave Schemelia ,Allogeneic Vsts ,Tiberend Strategic Advisors Inc ,Meeting Of The American Society Hematology ,Us Food Drug Administration ,Scientific Co ,Baylor College Of Medicine ,Baylor College ,Annual Meeting ,American Society ,Lead Principal Investigator ,Gene Therapy ,Danl Duncan Comprehensive Cancer Center ,Scientific Co Founder ,Chief Medical Officer ,Chief Scientific Officer ,Forward Looking ,Private Securities Litigation Reform Act ,Drug Administration ,Strategic Advisors ,Tessa ,Herapeutics ,Howcases ,Positive ,Linical ,Data ,Rom ,Hase ,Study ,Shelf ,Gd30 ,Fell ,Therapy ,021 ,Nnual ,Meeting ,Society ,Hematology ,